Chromogenic and fluorescent in situ hybridization in breast cancer.
Fluorescent (FISH) and chromogenic (CISH) in situ hybridization have recently become part of the diagnostic armamentarium of breast pathologists. HER2 gene testing by FISH and/or CISH has become an integral part of the diagnostic workup for patients with breast cancer. In this era of high throughput technologies, these techniques have proven instrumental for the validation of results from microarray-based comparative genomic hybridization and for the identification of novel oncogenes and tumor suppressor genes. Furthermore, FISH and CISH applied to tissue microarrays have expedited the characterization of genomic changes associated with specific breast cancer molecular subtypes and the identification of novel prognostic and predictive markers. In this review, we provide in this review a critical assessment of CISH and FISH and the impact of the analysis of amplification of specific oncogenes (eg, HER2, EGFR, MYC, CCND1, and FGFR1) and deletion of tumor suppressor genes (eg, BRCA1 and BRCA2) on our understanding of breast cancer.
Lambros
Maryou B K
MB
Molecular Pathology Laboratory, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, SW3 6JB London, UK.
Natrajan
Rachael
R
Reis-Filho
Jorge S
JS
D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism*; D002863:Chromogenic Compounds / Q000378:metabolism*; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D025202:Molecular Diagnostic Techniques; D046888:Tissue Array Analysis
D014408:Biomarkers, Tumor; D002863:Chromogenic Compounds; D004273:DNA, Neoplasm